

# Research Grade Diridavumab

## Summary

---


<b>Catalog No.</b>	DVV03801
<b>Alternative Names</b>	CR-6261, CR6261, CAS: 1393659-46-5
<b>Clone ID</b>	Diridavumab
<b>Host species</b>	Human
<b>Species reactivity</b>	Influenza A virus
<b>Form</b>	Liquid
<b>Storage buffer</b>	0.01M PBS, pH 7.4.
<b>Concentration</b>	2.76 mg/ml
<b>Purity</b>	>95% as determined by SDS-PAGE.
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1, lambda
<b>Applications</b>	Research Grade Biosimilar
<b>Target</b>	HA/Hemagglutinin
<b>Purification</b>	Protein A/G purified from cell culture supernatant.
<b>Endotoxin level</b>	Please contact with the lab for this information.
<b>Expression system</b>	Mammalian Cells
<b>Accession</b>	P03455
<b>Stability and Storage</b>	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

**Note** For research use only. Not suitable for clinical or therapeutic use.


## Description

Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).

## Data Image



SDS PAGE for Diridavumab



The purity of this product is >95% as determined by SEC-HPLC.

SEC-HPLC